TScan Therapeutics (TCRX) Competitors

Sage Therapeutics (NASDAQ:SAGE) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.

Do analysts rate SAGE or TCRX?

Sage Therapeutics currently has a consensus target price of $9.65, suggesting a potential upside of 31.97%. TScan Therapeutics has a consensus target price of $11.25, suggesting a potential upside of 418.43%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Sage Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sage Therapeutics	2 Sell rating(s)	16 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
TScan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer SAGE or TCRX?

Sage Therapeutics received 598 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 81.40% of users gave TScan Therapeutics an outperform vote while only 65.19% of users gave Sage Therapeutics an outperform vote.

Company	Underperform	Outperform
Sage Therapeutics	Outperform Votes 633 65.19%	Underperform Votes 338 34.81%
TScan Therapeutics	Outperform Votes 35 81.40%	Underperform Votes 8 18.60%

Do insiders and institutionals have more ownership in SAGE or TCRX?

99.2% of Sage Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by insiders. Comparatively, 2.8% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media refer more to SAGE or TCRX?

In the previous week, Sage Therapeutics had 11 more articles in the media than TScan Therapeutics. MarketBeat recorded 12 mentions for Sage Therapeutics and 1 mentions for TScan Therapeutics. Sage Therapeutics' average media sentiment score of 0.90 beat TScan Therapeutics' score of 0.00 indicating that Sage Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sage Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is SAGE or TCRX more profitable?

Sage Therapeutics has a net margin of -971.50% compared to TScan Therapeutics' net margin of -1,188.88%. TScan Therapeutics' return on equity of -58.72% beat Sage Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sage Therapeutics	-971.50%	-68.18%	-60.84%
TScan Therapeutics	-1,188.88%	-58.72%	-36.02%

Which has better earnings and valuation, SAGE or TCRX?

TScan Therapeutics has lower revenue, but higher earnings than Sage Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sage Therapeutics	$41.24M	10.90	-$400.67M	-$6.59	-1.11
TScan Therapeutics	$21.05M	5.50	-$89.22M	-$1.06	-2.05

Which has more risk & volatility, SAGE or TCRX?

Sage Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Summary

Sage Therapeutics beats TScan Therapeutics on 10 of the 18 factors compared between the two stocks.